• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Doxy 100
    / Vitamed

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    10 X 100 mg

    full basket chart 52769 4060

    Related information


    Acute infections: 200 mg on first day with food, then 100 mg daily.
    100 mg daily for 6-12 weeks.
    Malaria prophylaxis: 
    100 mg for 1-2 days prior to entering the malaria area.
    100 mg daily for the duration of stay. To continue for 3-4 weeks after leave.


    Infections due to tetracycline sensitivite bacteria, acne, prevention of malaria when other drugs not suitable or parasites resistant.


    Infancy and childhood up to 12 years of age. Doxycycline should not be administered to patients who have shown hypersensitivity to any of the ingredients of the preparation, or have shown hypersensitivity to any of the tetracyclines. The use of doxycycline is contra-indicated during pregnancy as it can have toxic effects on the developing foetus. Tetracyclines are also found in the milk of lactating women and should not be administered for more than 3 consecutive month period.

    Special Precautions

    Doxycycline should be administered with caution to patients with hepatic impairment or those receiving potentially hepatotoxic drugs. Care should be taken in the treatment of patients with myasthenia gravis who may be at risk of neuromuscular blockade. All patients receiving doxycycline should be advised to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy of phototoxicity if (e.g., skin eruption etc.) occurs. Should be used with caution in patients with a history of or predisposition to oral candidosis.

    Side Effects

    In the event of the development of diarrhea during treatment, the possibility of pseudomembranous colitis should be considered and appropriate therapy instituted.
    Gastrointestinal: Anorexia, nausea, vomiting, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions with monilial overgrowth in the anogenital region.
    Skin: Maculo papular and erythematous rashes. Skin photosensitivity can occur.

    Drug interactions

    Doxycycline has been shown to depress plasma prothrombin activity. Potentiates the effect of anticoagulants of the dicumarol type. Bacteriostatic drugs including doxycycline may interfere with the bacteriocidal action of penicillin and betalactam antibiotics. The use of certain antacids containing calcium, aluminium, magnesium or zinc, as well as iron-containing preparations, activated charcoal, cholestyramine, bismuth chelates and sucralfate, inhibit the absorption of tetracyclines. Therefore such medications or foodstuffs should be taken after a period of 2 to 3 hours following ingestion. Didanosine may decrease the absorption of doxycycline due to the gastric pH increase as a consequence of the antacid content of the didanosine tablets. Didanosine should therefore be taken at least 2 hours after doxycycline. Quinapril may reduce the absorption of doxycycline due to the high magnesium content in quinapril tablets. Doxycycline has been shown to potentiate the hypoglycemic effect of sulfonylurea oral antidiabetic agents. If administered in combination with these drugs, blood sugar levels should be monitored and if necessary, the doses of the above drugs reduced. When doxycycline is administered shortly before, during or after courses of isotretinoin, there is the possibility of potentiation between the drugs to cause reversible pressure increase in the intracranial cavity (pseudotumor cerebri). Concomitant administration should therefore be avoided. Rifampicin, barbiturates, carbamazepine, diphenylhydantoin, primidone, phenytoin, and chronic alcohol abuse may accelerate the decompostion of doxycycline due to enzyme induction in the liver thereby decreasing its half-life.

    Rekah Pharmaceutical Prod Ltd.